News

A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.
DelveInsight's HER2+ Gastric Cancer (including GEJ) Market report includes a comprehensive understanding of current treatment practices, emerging HER2+ gastric cancer therapies, market share of ...
The FDA has granted traditional approval to Keytruda (pembrolizumab) in combination with trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma.
HER2-mutation testing turnaround time varies, and interpreting results can be complex, requiring clear guidelines and expert input.
Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive results and favorable safety.
We identified GPRC5A and TPBG as potential biomarkers for a poor response to anti-HER2 therapy.” “Our proteogenomic analysis of CALGB 40601 revealed likely false-positives among patients diagnosed ...
The phase 3 VERITAC-2 trial, a significant PFS improvement with vepdegestrant was seen in patients with ER+/HER2- advanced breast cancer with ESR1 mutations.
RemeGen's China readout bodes well for Pfizer’s own global phase 3 trial that pairs disitamab vedotin with Keytruda in in first-line bladder cancer.
One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. Investigators of the Vall d'Hebron ...
Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a manageable safety profile.
Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, announced today that the US Food ...